Original article by Yolanda Redrup
The Australian Financial Review – Page: 15 : 15-Aug-19
Blood product company CSL released its results for the year to 30 June on 14 August, reporting a net profit after tax of $US1.92 billion ($2.9 billion), up 11 per cent. CSL’s revenue was up by 7.9 per cent to $US8.5 billion, while the company advised that it expected its net profit to exceed $US2 billion in the 2019-20 financial year. CSL CEO Paul Perreault called on its competitors in the global immunoglobulin market to boost their output, or risk demand significantly outweighing supply.
CSL LIMITED – ASX CSL